Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 7/20 | 0.54 |
| ▸ | BACE1 | P56817 | 4/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29940165 | 0.92 | BACE1 (0.57) | CTSDBACE1OPRM1OPRD1BACE2 | |
| SCHEMBL19878298 | 0.91 | BACE1 (0.57) | CTSDBACE1BACE2 | |
| SCHEMBL30799436 | 0.89 | BACE1 (0.58) | CTSDBACE1MMEOPRM1OPRD1 | |
| SCHEMBL31357930 | 0.88 | OPRM1 (0.56) | CTSDBACE1OPRM1OPRD1 | |
| SCHEMBL29603617 | 0.88 | ACE (0.60) | CTSDBACE1MMEACECPA1 | |
| SCHEMBL29603734 | 0.88 | ACE (0.60) | CTSDBACE1MMEACECPA1 | |
| SCHEMBL30815962 | 0.88 | BACE1 (0.56) | CTSDBACE1MMEACECPA1 | |
| SCHEMBL30426139 | 0.88 | BACE1 (0.54) | CTSDBACE1MMEACECPA1 | |
| SCHEMBL30901819 | 0.87 | BACE1 (0.58) | CTSDBACE1 | |
| SCHEMBL30051904 | 0.87 | MME (0.57) | CTSDMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098058-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | URTESTE S.A. (PL) | 2026-04-09 | — | — | US | claimed |
| EP-4594335-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | Urteste S.A. (PL) | 2025-08-06 | — | — | EP | claimed |
| CN-119998307-A | Compound-ovarian cancer diagnostic markers, method for detecting enzymatic activity, method for diagnosing ovarian cancer, kit comprising said compound, use of said compound and method for treating ovarian cancer | 尔特斯特公司 | 2025-05-13 | — | — | CN | claimed |
| WO-2024072241-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | URTESTE S.A. (PL) | 2024-04-04 | — | — | WO | claimed |
| US-20260098058-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | URTESTE S.A. (PL) | 2026-04-09 | — | — | US | disclosed |
| EP-4594335-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | Urteste S.A. (PL) | 2025-08-06 | — | — | EP | disclosed |
| CN-119998307-A | Compound-ovarian cancer diagnostic markers, method for detecting enzymatic activity, method for diagnosing ovarian cancer, kit comprising said compound, use of said compound and method for treating ovarian cancer | 尔特斯特公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024072241-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | URTESTE S.A. (PL) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098058-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | DNPEP, ANPEP, CA9 | CTSD 168/4885BACE1 492/4885MME 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.